Literature DB >> 3466184

Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection.

L R Williams, S Varon, G M Peterson, K Wictorin, W Fischer, A Bjorklund, F H Gage.   

Abstract

Neurons in the rat medial septum (MS) and vertical limb of the diagonal band of Broca (VDB) undergo a rapid and severe cell death after transection of their dorsal projection to the hippocampus by aspiration of the ipsilateral fimbria fornix and supracallosal striae. By 2 weeks posttransection, the extent of neuronal loss was 50% of the total neurons and 70% of the cholinergic neurons in the MS and 30% of the total neurons and 40% of the cholinergic neurons in the VDB. We hypothesized that (i) the death was due to the loss of a hippocampus-derived neuronotrophic factor, and (ii) exogenous nerve growth factor (NGF) might provide trophic support to the MS/VDB cholinergic neurons, in light of recent reports that the septal diagonal band cholinergic neurons are responsive to NGF and that NGF is present and produced in the hippocampus. In the present study, we attempted to prevent the transection-induced neuronal death by continuous infusion of exogenous 7S NGF (1 microgram/wk) through an intraventricular cannula device. We report here that NGF treatment significantly reduces both the total neuronal and cholinergic neuronal death found 2 weeks after fimbria fornix transection; there was a sparing of 50% of the neurons in the MS and essentially 100% of those in the VDB that otherwise would have died. We conclude that NGF also has a protective effect on noncholinergic neurons since calculations indicate that 80% of the NGF-affected neurons are noncholinergic.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3466184      PMCID: PMC387109          DOI: 10.1073/pnas.83.23.9231

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  51 in total

Review 1.  Nerve growth factor and its mode of action.

Authors:  S Varon
Journal:  Exp Neurol       Date:  1975-09       Impact factor: 5.330

2.  Local control of neurite development by nerve growth factor.

Authors:  R B Campenot
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

Review 3.  Regeneration of monoaminergic and cholinergic neurons in the mammalian central nervous system.

Authors:  A Björklund; U Stenevi
Journal:  Physiol Rev       Date:  1979-01       Impact factor: 37.312

4.  The cholinergic synapse and the site of memory.

Authors:  J A Deutsch
Journal:  Science       Date:  1971-11-19       Impact factor: 47.728

Review 5.  Physiology of nerve growth factor.

Authors:  H Thoenen; Y A Barde
Journal:  Physiol Rev       Date:  1980-10       Impact factor: 37.312

Review 6.  The nerve growth factor: biochemistry, synthesis, and mechanism of action.

Authors:  L A Greene; E M Shooter
Journal:  Annu Rev Neurosci       Date:  1980       Impact factor: 12.449

7.  Distribution of acetyl cholinesterase in the hippocampal region of the guinea pig. I. Entorhinal area, parasubiculum, and presubiculum.

Authors:  F A Geneser-Jensen; T W Blackstad
Journal:  Z Zellforsch Mikrosk Anat       Date:  1971

8.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

Review 9.  Dementia of the Alzheimer type.

Authors:  R D Terry; P Davies
Journal:  Annu Rev Neurosci       Date:  1980       Impact factor: 12.449

10.  Nerve growth factor (NGF) in the rat CNS: absence of specific retrograde axonal transport and tyrosine hydroxylase induction in locus coeruleus and substantia nigra.

Authors:  M E Schwab; U Otten; Y Agid; H Thoenen
Journal:  Brain Res       Date:  1979-06-08       Impact factor: 3.252

View more
  105 in total

Review 1.  Expression profiling following traumatic brain injury: a review.

Authors:  Paolo G Marciano; James H Eberwine; Ramesh Ragupathi; Kathryn E Saatman; David F Meaney; Tracy K McIntosh
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

Review 2.  Intrathecal drug administration. Present use and future trends.

Authors:  J S Kroin
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 3.  Gene therapy in clinical medicine.

Authors:  S M Selkirk
Journal:  Postgrad Med J       Date:  2004-10       Impact factor: 2.401

4.  Nerve growth factor corrects developmental impairments of basal forebrain cholinergic neurons in the trisomy 16 mouse.

Authors:  P Corsi; J T Coyle
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

5.  Nerve growth factor in the hippocamposeptal system: evidence for activity-dependent anterograde delivery and modulation of synaptic activity.

Authors:  Lan Guo; Mason L Yeh; Verginia C Cuzon Carlson; Erin M Johnson-Venkatesh; Hermes H Yeh
Journal:  J Neurosci       Date:  2012-05-30       Impact factor: 6.167

6.  Nerve growth factor (NGF) augments cortical and hippocampal cholinergic functioning after p75NGF receptor-mediated deafferentation but impairs inhibitory avoidance and induces fear-related behaviors.

Authors:  J Winkler; G A Ramirez; L J Thal; J J Waite
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

7.  Nerve growth factor mRNA and protein increase in hypothalamus in a mouse model of aggression.

Authors:  M G Spillantini; L Aloe; E Alleva; R De Simone; M Goedert; R Levi-Montalcini
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

8.  Nerve growth factor rapidly suppresses basal, NMDA-evoked, and AMPA-evoked nitric oxide synthase activity in rat hippocampus in vivo.

Authors:  H H Lam; A Bhardwaj; M T O'Connell; D F Hanley; R J Traystman; M V Sofroniew
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

9.  Growth control of C6 glioma in vivo by nerve growth factor.

Authors:  Shigeyoshi Kimura; Atsuo Yoshino; Yoichi Katayama; Takao Watanabe; Takao Fukushima
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

10.  Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP + PS1 transgenic mice.

Authors:  Niki C Carty; Kevin Nash; Daniel Lee; Mary Mercer; Paul E Gottschall; Craig Meyers; Nicholas Muzyczka; Marcia N Gordon; Dave Morgan
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.